PRAX vs. GLTO, CLSD, VIRX, IMNM, IPA, LGVN, FBIO, SCTL, CNTB, and ADAG
Should you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Galecto (GLTO), Clearside Biomedical (CLSD), Viracta Therapeutics (VIRX), Immunome (IMNM), ImmunoPrecise Antibodies (IPA), Longeveron (LGVN), Fortress Biotech (FBIO), Societal CDMO (SCTL), Connect Biopharma (CNTB), and Adagene (ADAG). These companies are all part of the "pharmaceutical preparations" industry.
Praxis Precision Medicines vs.
Praxis Precision Medicines (NASDAQ:PRAX) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations.
Galecto is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.
Galecto received 14 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. Likewise, 62.79% of users gave Galecto an outperform vote while only 52.00% of users gave Praxis Precision Medicines an outperform vote.
89.3% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 35.8% of Galecto shares are held by institutional investors. 10.5% of Praxis Precision Medicines shares are held by insiders. Comparatively, 9.2% of Galecto shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Praxis Precision Medicines currently has a consensus price target of $10.25, indicating a potential upside of 1,068.62%. Galecto has a consensus price target of $11.67, indicating a potential upside of 445.17%. Given Praxis Precision Medicines' higher probable upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Galecto.
Praxis Precision Medicines has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, Galecto has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.
In the previous week, Galecto had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 2 mentions for Galecto and 0 mentions for Praxis Precision Medicines. Galecto's average media sentiment score of 0.75 beat Praxis Precision Medicines' score of 0.00 indicating that Galecto is being referred to more favorably in the news media.
Galecto's return on equity of -85.49% beat Praxis Precision Medicines' return on equity.
Summary
Galecto beats Praxis Precision Medicines on 10 of the 15 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Praxis Precision Medicines Competitors List
Related Companies and Tools